Wednesday, September 2
Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1, Plexiform Neurofibromas, and Optic Pathway Gliomas: Improving Patient Outcomes With an Innovative Therapeutic Approach (SY1)
Join us for this PeerView educational activity on neurofibromatosis type 1 (NF-1) and plexiform neurofibromas (PNs). An expert panel will provide insight into the expanding landscape of targeted therapies and will discuss optimal clinical decision-making for patients with NF-1 and NF-1─related PNs that are based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.
APHON thanks Astra Zeneca for their generous support of this event.